Obesity-Related Complications Including Dysglycemia Based on 1-h Post-Load Plasma Glucose in Children and Adolescents Screened before and after COVID-19 Pandemic.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Publishing Country of Publication: Switzerland NLM ID: 101521595 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6643 (Electronic) Linking ISSN: 20726643 NLM ISO Abbreviation: Nutrients Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI Publishing
    • Subject Terms:
      COVID-19*/epidemiology ; COVID-19*/blood ; COVID-19*/complications ; Blood Glucose*/metabolism ; Blood Glucose*/analysis ; Prediabetic State*/blood ; Prediabetic State*/epidemiology ; Prediabetic State*/diagnosis ; Pediatric Obesity*/complications ; Pediatric Obesity*/blood ; Pediatric Obesity*/epidemiology ; Glucose Tolerance Test* ; Diabetes Mellitus, Type 2*/blood ; Diabetes Mellitus, Type 2*/complications ; Diabetes Mellitus, Type 2*/epidemiology; Humans ; Child ; Adolescent ; Female ; Male ; SARS-CoV-2 ; Hyperglycemia/blood ; Hyperglycemia/epidemiology ; Insulin Resistance ; Pandemics
    • Abstract:
      Childhood obesity, with its metabolic complications, is a problem of public health. The International Diabetes Federation (IDF) has recommended glucose levels 1 h post oral glucose load (1h-PG) > 155-209 mg/dL as diagnostic for intermediate hyperglycemia (IH), while >209 mg/dL for type 2 diabetes (T2D). The aim of the study was to assess the occurrence of prediabetes, IH, and T2D in children and adolescents with simple obesity according to the criteria of American Diabetes Association (ADA) and of IDF, and the effect of COVID-19 pandemic on these disorders. Analysis included 263 children with simple obesity, screened either in prepandemic (PRE-113 cases) or post-pandemic period (POST-150 cases). All children underwent 2 h OGTT with measurements of glucose and insulin every 0.5 h, lipid profile, and other tests; indices if insulin resistance (IR): HOMA, QUICKI, Matsuda index, AUC (glu/ins) were calculated. The incidence of T2D, prediabetes, and IH was higher in POST with respect to PRE, with significant differences in the indices of IR, except for HOMA. Significant differences were observed in the assessed parameters of glucose metabolism among the groups with T2D, prediabetes, IH, and normal glucose tolerance (NGT), with some similarities between IH (based on 1h-PG) and prediabetes. Increased frequency of dysglycemia among children and adolescents with simple obesity is observed after COVID-19 pandemic. Metabolic profile of patients with IH at 1h-PG is "intermediate" between NGT and prediabetes.
    • References:
      Pediatr Obes. 2024 Aug;19(8):e13128. (PMID: 38812373)
      BioTech (Basel). 2024 Jul 01;13(3):. (PMID: 39051337)
      J Cyst Fibros. 2014 Jan;13(1):80-5. (PMID: 23809507)
      Eur J Pediatr. 2013 Jun;172(6):753-61. (PMID: 23371392)
      Interdiscip Perspect Infect Dis. 2024 May 13;2024:7212355. (PMID: 38770046)
      Minerva Pediatr (Torino). 2024 Jun 04;:. (PMID: 38837204)
      Pediatr Endocrinol Diabetes Metab. 2023;29(2):104-111. (PMID: 37728462)
      J Pediatric Infect Dis Soc. 2024 Jul 20;13(7):352-362. (PMID: 38780125)
      Nutrients. 2024 Jul 11;16(14):. (PMID: 39064660)
      Eur J Pediatr. 2011 May;170(5):599-609. (PMID: 20972688)
      Nutrients. 2023 Dec 23;16(1):. (PMID: 38201884)
      Int J Obes (Lond). 2023 Apr;47(4):257-262. (PMID: 36670156)
      Lancet Diabetes Endocrinol. 2024 Jul;12(7):462-471. (PMID: 38843849)
      Cureus. 2023 Sep 18;15(9):e45470. (PMID: 37859918)
      Front Physiol. 2024 Jul 10;15:1399407. (PMID: 39050483)
      J Endocrinol Invest. 2023 Aug;46(8):1685-1694. (PMID: 36763246)
      Children (Basel). 2024 Apr 28;11(5):. (PMID: 38790523)
      Ann Agric Environ Med. 2024 Mar 25;31(1):78-86. (PMID: 38549480)
      JMIR Res Protoc. 2024 Jun 20;13:e48549. (PMID: 38900565)
      Sci Rep. 2021 Apr 15;11(1):8224. (PMID: 33859227)
      PLoS Med. 2024 Jun 24;21(6):e1004398. (PMID: 38913709)
      Diabetes Res Clin Pract. 2024 Mar;209:111589. (PMID: 38458916)
      J Clin Med. 2024 May 26;13(11):. (PMID: 38892825)
      Diabetes Care. 2022 Jan 1;45(Suppl 1):S17-S38. (PMID: 34964875)
      J Public Health (Oxf). 2024 May 29;46(2):223-229. (PMID: 38324401)
      Diabetes Res Clin Pract. 2024 Jun;212:111692. (PMID: 38723673)
      Annu Rev Public Health. 2021 Apr 1;42:59-77. (PMID: 33355476)
      Hosp Pharm. 2024 Jun;59(3):341-348. (PMID: 38764990)
      Am J Physiol Endocrinol Metab. 2024 Apr 1;326(4):E454-E471. (PMID: 38054972)
      J Sports Sci. 2024 Apr;42(8):688-700. (PMID: 38819118)
      Adv Mind Body Med. 2024 Winter;28(1):15-19. (PMID: 38787682)
      Pediatr Endocrinol Diabetes Metab. 2022;28(4):274-280. (PMID: 36734390)
      JAMA. 2021 Oct 12;326(14):1434-1436. (PMID: 34448817)
      Pediatr Clin North Am. 2024 Aug;71(4):645-652. (PMID: 39003007)
      Pediatr Res. 2024 May;95(6):1649-1657. (PMID: 38238565)
      Int J Obes (Lond). 2024 Jun 7;:. (PMID: 38849462)
      J Hum Nutr Diet. 2024 Jul 11;:. (PMID: 38990157)
      JAMA Pediatr. 2024 May 1;178(5):498-500. (PMID: 38497991)
      Lancet Diabetes Endocrinol. 2017 Jan;5(1):5-7. (PMID: 27863980)
      Obesity (Silver Spring). 2024 Aug;32(8):1474-1482. (PMID: 38946013)
      Medicine (Baltimore). 2024 May 24;103(21):e38266. (PMID: 38787973)
      Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2024 Aug;67(8):939-946. (PMID: 39012367)
      Front Endocrinol (Lausanne). 2024 Apr 23;15:1343641. (PMID: 38715798)
      Nutrients. 2024 Jul 07;16(13):. (PMID: 38999909)
      Front Endocrinol (Lausanne). 2022 Oct 31;13:992264. (PMID: 36387906)
      World J Hepatol. 2024 Jun 27;16(6):912-919. (PMID: 38948433)
      J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10. (PMID: 10902785)
      J Diabetes Res. 2024 Mar 20;2024:5558634. (PMID: 38550917)
      J Biosoc Sci. 2024 Apr 15;:1-10. (PMID: 38618941)
      Diabetologia. 1985 Jul;28(7):412-9. (PMID: 3899825)
      JMIR Form Res. 2024 May 14;8:e49168. (PMID: 38743472)
      J Clin Med. 2023 Sep 12;12(18):. (PMID: 37762850)
      Biochim Biophys Acta Mol Basis Dis. 2024 Jun 26;1870(7):167322. (PMID: 38942338)
      J Infect Public Health. 2024 May;17(5):795-799. (PMID: 38520760)
      Pediatr Ann. 2024 Jul;53(7):e249-e253. (PMID: 38949870)
      Sports Med Open. 2024 Mar 1;10(1):20. (PMID: 38429549)
      Pediatr Rep. 2024 Feb 02;16(1):135-150. (PMID: 38391001)
      BMC Nutr. 2024 Feb 5;10(1):27. (PMID: 38317176)
      Pediatr Diabetes. 2018 Nov;19(7):1173-1182. (PMID: 29885044)
      Eur Rev Med Pharmacol Sci. 2021 Oct;25(19):5986-5992. (PMID: 34661258)
      Ann Pediatr Endocrinol Metab. 2024 Jun 05;:. (PMID: 38853577)
    • Contributed Indexing:
      Keywords: insulin resistance; intermediate hyperglycemia; metabolic profile; oral glucose tolerance test; prediabetes; simple obesity; type 2 diabetes
    • Accession Number:
      0 (Blood Glucose)
    • Publication Date:
      Date Created: 20240810 Date Completed: 20240810 Latest Revision: 20240812
    • Publication Date:
      20240813
    • Accession Number:
      PMC11314267
    • Accession Number:
      10.3390/nu16152568
    • Accession Number:
      39125447